top of page

Research & Development

As Multidrug Resistant (MDR-MRSA) bacteria such as Pseudomonas Aeruginosa or Staphylococcus Aureus continue to perplex the medical community, Pharmotech SA offers hope through a collaborative R&D approach with Swiss Primary Scientific Institutions.

Supporting Clinics

With real-world implementation in mind, Pharmotech SA leverages proof- of concept (PoC) clinical trials to bridge the gap between lab work and clinical applications. These small-scale studies identify high-potential drug candidates while revealing key considerations.

Key Considerations:

Safety - evaluating for potential toxicity, reactions, and side effects

Dosage - determining the optimal dose for the best possible results

Efficacy - assessing the effectiveness against MDR-MRSA bacteria

Global Impact

As Pharmotech SA continues to conduct R&D, perform trials, and develop patents, millions of patients, healthcare professionals, and animals worldwide will benefit. In the interim, the team remains steadfast in all research efforts and go-to-market strategies. 

bottom of page